P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex
This article was originally published in The Pink Sheet Daily
Executive Summary
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.